Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.
Accolade, Inc. (Nasdaq: ACCD) is a pioneering Personalized Healthcare company devoted to providing exceptional healthcare experiences to millions of people and their families, enabling them to live their healthiest lives. Accolade's range of solutions targets employers, health plans, and consumers by integrating virtual primary care, mental health services, expert medical opinions, and top-tier care navigation. Their innovative platform leverages cloud-based intelligent technology, coupled with expert clinical teams, including registered nurses, physician medical directors, pharmacists, and primary care physicians, to deliver comprehensive advocacy and healthcare services.
The company has been recognized for its significant contributions to the healthcare industry, such as being named one of Forbes' 25 most promising companies and achieving a spot on Inc. 500's list of America's fastest-growing private companies. Accolade's mission is to guide individuals through the complexities of the healthcare system, thereby enhancing outcomes and reducing costs for employers and health plans.
Accolade has recently gained considerable attention for its impressive 227% revenue growth, attributed to a relentless focus on delivering exceptional outcomes. This achievement earned Accolade a place in the Deloitte Technology Fast 500™ list for 2023. CEO Rajeev Singh credits the company's innovative approach and dedicated team for this remarkable performance.
Accolade's Trusted Partner Ecosystem, launched in 2019, exemplifies its commitment to comprehensive healthcare solutions. This ecosystem includes partnerships with leading companies like Kindbody and Noom, expanding access to specialized services such as fertility and metabolic health.
Accolade's financial health remains robust, with recent quarterly results showcasing a significant reduction in net loss and positive adjusted EBITDA, indicating a promising trajectory toward sustainable growth and profitability.
With a consumer satisfaction rating consistently over 90%, Accolade is steadily advancing its vision of transforming healthcare through predictive engagement, proactive care, and by addressing barriers to access and continuity of care. The company's forward-thinking approach ensures it remains at the forefront of healthcare innovation, making a significant impact on the industry and the lives of the people it serves.
For more information, visit accolade.com.
Accolade (NASDAQ: ACCD) announced its fiscal first-quarter 2025 results, highlighting significant improvements. The company reported a revenue increase of 18% year-over-year, reaching $110.5 million. Net loss improved by 28%, down to $27.6 million from $38.4 million in the same period last year. Adjusted EBITDA saw a substantial improvement of 73%, landing at negative $3.3 million compared to negative $12.6 million. Adjusted gross profit also rose by 30%, totaling $52.8 million, with an adjusted gross margin of 47.8%, up from 43.5%.
CEO Rajeev Singh emphasized Accolade's continued focus on healthcare accessibility and outcomes through their physician-led advocacy approach. CFO Steve Barnes highlighted the company's commitment to achieving profitable growth and positive Adjusted EBITDA within the year.
Accolade (NASDAQ: ACCD) announced the release date for its fiscal first quarter 2025 financial results. The report will be available on June 27, 2024, after the market closes. A conference call to review these results is scheduled for the same day at 4:30 p.m. ET. Interested parties must pre-register for the call, which will be accessible via telephone and a live audio webcast on Accolade's investor relations website. A replay of the call will be available for one year.
Accolade (NASDAQ: ACCD) has announced its participation in the William Blair Growth Stock Conference in Chicago. The company will present on June 4, 2024, at 2:00 pm CT. A webcast and a 90-day replay will be available on their investor relations website.
Accolade (Nasdaq: ACCD) has announced a partnership with Noom to enhance its Trusted Partner Ecosystem. This collaboration offers a comprehensive solution for weight loss and metabolic health, integrating Noom's coaching with Accolade's primary care physicians. Noom Med, part of this partnership, focuses on obesity management, including GLP-1 medications and other anti-obesity drugs. Noom's approach combines psychology, science, and personalized support, achieving a 25% employee adoption rate and 42% of users maintaining weight loss for two years. This partnership aims to reduce obesity-related healthcare costs and improve outcomes through evidence-based care and advanced primary care support.
FAQ
What does Accolade, Inc. do?
How has Accolade performed financially recently?
What is the Trusted Partner Ecosystem?
Who are Accolade's key partners?
What recognition has Accolade received?
What is Accolade's mission?
How does Accolade contribute to healthcare cost reduction?
How does Accolade engage with its members?
What is Accolade's customer satisfaction rating?
Where can I find more information about Accolade?
